⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 8, 2004Thrombosis and HaemostasisOpen Access

Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin

View Full Paper

Ask AI

Bookmark

Share

Population

Patients with type-2 diabetes

Design

Review

Authors

LTLicia TotaniMario Negri Sud Foundation SRSerenella RotondoMario Negri Institute for Pharmacological Research RLRoberto LorenzetUniversità Cattolica del Sacro Cuore

Discussion

Loading...

Member takes

Implication

May limit aspirin use in diabetes; leaves open need for targeted antithrombotic trials.

Structured PICO

P

Population

Patients with type-2 diabetes

I

Intervention

Low-dose aspirin and adjuvant therapies

This review highlights the reduced clinical efficacy of low-dose aspirin in patients with type-2 diabetes and discusses potential mechanisms and adjuvant therapies to improve its antithrombotic activity.

Cite This Study

Totani et al. (2004) studied this question.

synapsesocial.com/papers/6a7038c335aa2c282ce18641 https://doi.org/10.1160/th04-07-0453

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/β-Blocker–Based Treatment Regimen2001 · 217 citations
2Potent Inhibitory Effect of Troglitazone on Carotid Arterial Wall Thickness in Type 2 Diabetes1998 · 452 citations
3Platelet activation in diabetic cardiovascular autonomic neuropathy1999 · 39 citations
4Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.1998 · 75 citations
5The Effects of Angiotensin Metabolites on the Regulation of Coagulation and Fibrinolysis in Cultured Rat Aortic Endothelial Cells1999 · 52 citations